The cannabis industry is cautiously optimistic about the incoming Trump administration, despite Trump’s controversial views on marijuana. While Trump has expressed support for marijuana legalization in the past, his cabinet picks and nominees have raised concerns among industry advocates. However, many entrepreneurs and advocates believe that the industry’s momentum will continue, driven by growing public support for legalization and the increasing number of states that have legalized cannabis.
The industry’s optimism is fueled by Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS), who has expressed support for cannabis and psychedelics. Additionally, Trump’s nominee to head the Food and Drug Administration (FDA), Marty Makary, has suggested that cannabis use can be linked to cardiovascular and mental health issues, which could potentially lead to a reevaluation of the drug’s scheduling.
Despite these positive developments, the industry is also wary of Trump’s anti-marijuana record and the potential for his administration to roll back progress on legalization. The appointment of Pam Bondi, who opposed medical marijuana in Florida, as attorney general has raised concerns among advocates.
Industry insiders are also watching the Trump administration’s plans for federal cannabis policy, including the potential for interstate commerce and the impact on small businesses. While some are optimistic about the potential for disruption and change, others are more cautious, recognizing that the industry’s progress has been slow and incremental.
Overall, the cannabis industry is waiting to see what the Trump administration will do, but many are cautiously optimistic that the momentum for legalization will continue. As one industry veteran said, “We will see.”
